From Growth factor shows promise for Phelan-McDermid syndrome
"Last week, a separate set of researchers announced that the drug appears to be safe and effective in a trial of 53 adolescents and adults with Rett syndrome."
The inference is that IGF-1 was the drug being used instead of NNZ-2566. Only later on do you learn that:
"The Rett trial uses a modified form of IGF-1 that includes only the first three amino acids, but which may induce production of the full-length form in the brain"
I have noticed in a number of articles IGF-1 was being hyped and NNZ-2566 downplayed or not mentioned (as in the above announcement). To me IGF-1 is a competitor.
Wider autism efficacy potential for nnz-2566, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.57 |
Change
-0.040(0.27%) |
Mkt cap ! $1.813B | |||
| Open | High | Low | Value | Volume |
| $14.94 | $15.19 | $14.51 | $8.165M | 551.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2735 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.65 | 1396 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |